The discovery and development of vilazodone for the treatment of depression: a novel antidepressant or simply another SSRI?

Bibliography

• Woolley DW, Shaw E. A biochemical and pharmacological suggestion about certain mental disorders. Proc Natl Acad Sci USA 1954;40:228-31
   PubMed Web of Science ®Google Scholar
• Goodwin FK, Bunney WE Jr. Depressions following reserpine: a re-evaluation. Semin Psychiatry 1971;3:435-48
   PubMedGoogle Scholar
• Shopsin B. Enhancement of the antidepressant response to L-tryptophan by a liver pyrrolase inhibitor: a rational treatment. Neuropsychobiology 1978;4:188-92
   PubMed Web of Science ®Google Scholar
• Delgado JMR, Charney DS, Price LH, et al. Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant - induced remission by rapid depletion of plasma tryptophan. Arch Gen Physchiatr 1990;47:411-18
   PubMed Web of Science ®Google Scholar
• Coppen A, Shaw DM, Herzberg B, Maggs R. Tryptophan in the treatment of depression. Lancet 1967;2:1178-80
   PubMed Web of Science ®Google Scholar
• Coppen A, Shaw DM, Malleson A, et al. Tryptamine metabolism in depression. Br J Psychiatr 1967;111:993-8
   Web of Science ®Google Scholar
• Cowen PJ. A role for 5-HT in the action of antidepressant drugs. Pharmacol Ther 1990;46:43-51
   PubMed Web of Science ®Google Scholar
• Artigas F, Perez V, Alvarez E. Pindolol induces a rapid improvement of patients with depression treated with serotonin re-uptake inhibitors. Arch Gen Psychiatr 1994;51:248-51
   PubMed Web of Science ®Google Scholar
• Blier P, Bergeron R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychopharmacol 1995;15:217-22
   PubMed Web of Science ®Google Scholar
• Svensson TH. Attenuated feed-back inhibition of brain serotonin synthesis following chronic administration of imipramine. Naunyn Schmiedeberg's Arch Pharmacol 1978;302:115-18
   Google Scholar
• Blier P. Altered function of the serotonin 1A autoreceptor and the antidepressant response. Neuron 2010;65:1-2
   PubMed Web of Science ®Google Scholar
• Blier P. Rational site-directed pharmacotherapy for major depressive disorder. Int J Neuropsychopharmacol 2013; doi: 10.1017/S146114571300028X
   Web of Science ®Google Scholar
• Celada P, Bortolozzi A, Artigas F. Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research. CNS Drugs 2013; doi: 10.1007/s40263-013-0071-0
   PubMed Web of Science ®Google Scholar
• Blier P, Chaput Y, De Montigny C. Long-term 5-HT re-uptake blockade, but not monoamine oxidase inhibition, decreases the function of terminal 5-HT autoreceptors: an electrophysiological study in the rat brain. Naunyn-Schmiedeberg's Arch. Pharmacology 1988;337:246-54
   Web of Science ®Google Scholar
• Dawson LA, Nguyen HQ, Smith DL, Schechter LE. Effect of chronic fluoxetine and WAY-100635 treatment on serotonergic neurotransmission in the frontal cortex. J Psychopharmacol 2002;16:145-52
   PubMed Web of Science ®Google Scholar
• Dawson LA, Nguyen HQ, Smith DL, Schechter LE. Effects of chronic fluoxetine treatment, in the presence and absence (±) pindolol: a microdialysis study. Br J Pharmacol 2000;130:797-804
   PubMed Web of Science ®Google Scholar
• Hervas I, Vilaro MT, Romero L, et al. Desensitization of 5-HT1A autoreceptors by a low chronic fluoxetine dose effect of the concurrent administration of WAY-100635. Neuropsychopharmacology 2001;24:11-20
   PubMed Web of Science ®Google Scholar
• Neumaier JF, Root DC, Hamblin MW. Chronic fluoxetine reduces serotonin transporter mRNA and 5-HT1B mRNA in a sequential manner in the rat dorsal raphe nucleus. Neuropsychopharmacology 1996;15:515-22
   PubMed Web of Science ®Google Scholar
• Chang CM, Sato S, Han C. Evidence for the benefits of nonantipsychotic pharmacological augmentation in the treatment of depression. CNS Drugs 2013;27(Suppl 1):21-7.
   PubMed Web of Science ®Google Scholar
• Dawson LA, Bromidge SM. 5-HT1 Receptor augmentation strategies as enhanced efficacy therapeutics for psychiatric disorders. Curr Topics Med Chem 2008;8:1008-23
   PubMed Web of Science ®Google Scholar
• Heinrich T, Böttcher H, Gericke R, et al. Synthesis and structure–activity relationship in a class of indolebutylpiperazines as dual 5-HT1A receptor agonists and serotonin reuptake inhibitors. J Med Chem 2004;47:4684-92
   PubMed Web of Science ®Google Scholar
• Heinrich T, Böttcher H, Schiemann K, et al. Dual 5-HT1A agonists and 5-HT re-uptake inhibitors by combination of indole-butyl-amine and chromenonyl-piperazine structural elements in a single molecular entity. Bioorg Med Chem 2004;12:4843-52
   PubMed Web of Science ®Google Scholar
• Heinrich T, Böttcher H. A new synthesis of indole 5-carboxylic acids and 6-hydroxy-indole-5-carboxylic acids in the preparation of an o-hydroxylated metabolite of vilazodone. Bioorg Med Chem Lett 2004;14:2681-4
   PubMed Web of Science ®Google Scholar
• Merck GmbH: piperidine and piperazine derivatives which affect the CNS. EP 648767 A1; 1993
   Google Scholar
• Merck GmbH: novel use of 1-4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and its physiologically acceptable salts. WO2000072832; 2000
   Google Scholar
• Merck/SB/HGS Collaboration and License Agreement. 1996. Available from: http://contracts.onecle.com/hgs/smithkline.collab.1996.07.10.shtml [Last accessed 3 August 2013]
   Google Scholar
• Dawson LA, Watson JM. Vilazodone: a 5-HT1A receptor agonist/ serotonin transporter inhibitor for the treatment of affective disorders. CNS Neurosci. Theraphy 2009;15:107-17
   Google Scholar
• GSK. Merck KgaA agrees to end joint Vilazodone development. http://www.lexdon.com/article/gsk_merck_kgaa_agree_to/125249.html [Last accessed 16 August 2013]
   Google Scholar
• Genaissance licenses Merck KgaA's vilazodone. The Pharma Letter. 2004. Available from: http://www.thepharmaletter.com/file/79968/genaissance-licenses-merck-kgaas-vilazodone.html [Last accessed 3 August 2013]
   Google Scholar
• FDA approval of vilazodone. 2011. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm240642.htm [Last accessed 16 August 2013]
   Google Scholar
• Forest Labs to acquire Clinical Data for $1.2 billion. Reuters. 2011. Available from: http://www.reuters.com/article/2011/02/22/us-forest-clinicaldata-idUSTRE71L3N420110222 [Last accessed 3 August 2013]
   Google Scholar
• Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized Anxiety Disorder. US National Institutes of Health, clinicaltrials.gov. 2013. Available from: http://clinicaltrials.gov/show/NCT01844115 Last accessed 7 August 2013]
   Google Scholar
• Study of Vilazodone to Treat Social Anxiety Disorder. US National Institutes of Health, clinicaltrials.gov. 2013. Available from: http://clinicaltrials.gov/show/NCT01712321) [Last accessed 7 August 2013]
   Google Scholar
• Hewitt NJ, Hewitt P. Phase I and II enzyme characterization of two sources of HepG2 cell lines. Xenobiotica 2004;34:243-56
   PubMed Web of Science ®Google Scholar
• Ashby CR Jr, Kehne JH, Bartoszyk GD, Renda MJ, et al. Electrophysiological evidence for rapid 5-HT1A autoreceptor inhibition by vilazodone, a 5-HT1A receptor partial agonist and 5-HT reuptake inhibitor. Eur J Pharmacol 2013; doi: 10.1016/j.ejphar.2013.07.014
   PubMed Web of Science ®Google Scholar
• Bartoszyk GD, Barber A, Böttcher H, et al. Pharmacological profile of the mixed 5HT-re-uptake inhibitor/5HT1A-agonist EMD 68843. Soc Neurosci Abstr 1996;22:613
   Google Scholar
• Bartoszyk GD, Hegenbart R, Ziegler H. EMD 68843, a serotonin re-uptake inhibitor with selective presynaptic 5-HT1A receptor agonistic properties. Eur J Pharmacol 1997;322:147-53
   PubMed Web of Science ®Google Scholar
• Watson J, Collin L, Ho M, et al. 5-HT1A receptor agonist-antagonist binding affinity difference as a measure of intrinsic activity in recombinant and native tissue systems. Br J Pharmacol 2000;130:1108-14
   PubMed Web of Science ®Google Scholar
• Page ME, Cryan JF, Sullivan A, et al. Behavioral and neurochemical effects of 5-{4-[4-(5-cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl}-benzofuran-2-carboxamide (EMD 68843): a combined selective inhibitor of serotonin re-uptake and 5-hydroxytryptamine(1A) receptor partial agonist. J Pharmacol Exp Ther 2002;302:1220-7
   PubMed Web of Science ®Google Scholar
• Watson J, Brough S, Coldwell MC, et al. Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors. Br J Pharmacol 1998;125:1413-20
   PubMed Web of Science ®Google Scholar
• Hughes ZA, Starr KR, Langmead CJ, et al. Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin re-uptake inhibitor, vilazodone. Eur J Pharmacol 2005;510:49-57
   PubMed Web of Science ®Google Scholar
• Meller E, Goldstein M, Bohmaker K. Receptor reserve for 5-hydroxytryptamine1A-mediated inhibition of serotonin synthesis: possible relationship to anxiolytic properties of 5-hydroxytryptamine agonists. Mol Pharmacol 1990;37:231-7
   PubMed Web of Science ®Google Scholar
• Alper RH, Nelson DL. Inactivation of 5-HT1A receptors in hippocampal and cortical homogenates. Eur J Pharmacol 2000;390:67-73
   PubMed Web of Science ®Google Scholar
• Yocca FD, Eison AS, Hyslop DK, et al. Unique modulation of central 5-HT2 receptor binding sites and 5-HT2 receptor-mediated behavior by continuous gepirone treatment. Life Sci 1991;49:1777-85
   PubMed Web of Science ®Google Scholar
• Kehne JH, Bartoszyk GD, Greiner HE, et al. In vivo and ex vivo characterization of vilazodone as a serotonin reuptake inhibitor and 5-HT1A receptor partial agonist. Biol Psychiatry 2010;67(Suppl 1):823
   PubMedGoogle Scholar
• Done CJG, Sharp T. Biochemical evidence for the regulation of central noradrenergic activity by 5-HT1A and 5-HT2 receptors - microdialysis studies in the awake and anaesthetized rat. Neuropharmacology 1994;33:411-21
   PubMed Web of Science ®Google Scholar
• Chen NH, Reith MEA. Monoamine interactions measured by microdialysis in the ventral tegmental area of rats treated systemically with (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin. J Neurochem 1995;64:1585-97
   PubMed Web of Science ®Google Scholar
• Suzuki M, Matsuda T, Asano S, et al. Increase of noradrenaline release in the hypothalamus of freely moving rat by postsynaptic 5-hydroxytryptamine(1A) receptor activation. Br J Pharmacol 1995;115:703-11
   PubMed Web of Science ®Google Scholar
• Roberts C, Hagan JJ, Bartoszyk GD, Kew JNC. Effect of vilazodone on 5-HT efflux and re-uptake in the guinea pig dorsal raphe nucleus. Eur J Pharmacol 2005;517:59-63
   PubMed Web of Science ®Google Scholar
• O'Connell MT, Sarna GS, Curzon G. Evidence for postsynaptic mediation of the hypothermic effect of 5HT1A receptor activation. Br J Pharmacol 1992;106:603
   PubMed Web of Science ®Google Scholar
• Peglion J-L, Canton H, Bervoets K, et al. Characterization of potent and selective antagonists at postsynaptic 5-HT1A receptors in a series of N4-substituted arylpiperazines. J Med Chem 1995;38:4044
   PubMed Web of Science ®Google Scholar
• Thielen RJ, Frazer A. Effects of novel 5-HT1A receptor antagonists on measures of postsynaptic 5-HT1A receptor activation in vivo. Life Sci 1995;56:PL-163
   Google Scholar
• Hjorth S, Sharp T. Effect of the 5-HT1A receptor agonist 8-OH-DPAT on the release of 5-HT in dorsal and median raphe-innervated rat brain regions as measured by in vivo microdialysis. Life Sci 1991;48:1779-86
   PubMed Web of Science ®Google Scholar
• Dawson LA, Nguyen HQ. Effects of 5-HT1A receptor antagonists on fluoxetine-induced changes in serotonin in rat frontal cortex. Eur J Pharmacol 1998;345:41-6
   PubMed Web of Science ®Google Scholar
• Romero L, Celada P, Martin-Ruiz R, et al. Modulation of serotonergic function in rat brain by VN2222, a serotonin re-uptake inhibitor and 5-HT1A receptor agonist. Neuropsychopharmacology 2003;28:445-56
   PubMed Web of Science ®Google Scholar
• Carr GV, Lucki I. The role of serotonin receptor subtypes in treating depression: a review of animal studies. Psychopharmacology 2011;213:265-87
   PubMed Web of Science ®Google Scholar
• De Vry J, Benz U, Schreiber R, Traber J. Shock-induced ultrasonic vocalization in young adult rats: a model for testing putative anti-anxiety drugs. Eur J Pharmacol 1993;249:331-9
   PubMed Web of Science ®Google Scholar
• Treit D, Degroot A, kashluba S, Bartoszyk GD. Systemic EMD 68843 injections reduce anxiety in the shock-probe, but not the plus-maze test. Eur J Pharmacol 2001;414:245-8
   PubMed Web of Science ®Google Scholar
• Adamec R. Transmitter systems involved in neural plasticity underlying increased anxiety and defence—implications for understanding anxiety following traumatic stress. Neurosci Biobehav 1997;21:755-65
   PubMed Web of Science ®Google Scholar
• Adamec R, Bartoszyk GD, Burton P. Effects of systemic injections of vilazodone, a selective serotonin re-uptake inhibitor and serotonin 1A receptor agonist, on anxiety induced by predator stress in rats. Eur J Pharmacol 2004;504:65-77
   PubMed Web of Science ®Google Scholar
• Porsolt RD, Bertin A, Jalfre M. Behavioural despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977;229:327-36
   PubMedGoogle Scholar
• Porsolt RD, Le Pichon M, Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977;266:730-2
   PubMed Web of Science ®Google Scholar
• Lucki I. The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behav Pharmacol 1997;8:523-32
   PubMed Web of Science ®Google Scholar
• Singh A, Lucki I. Antidepressant-like activity of compounds with varying efficacy at 5-HT1A receptors. Neuropharmacology 1993;32:331-42
   PubMed Web of Science ®Google Scholar
• Mayorga AJ, Dalvi A, Page ME, et al. Antidepressant-like behavioral effects in 5-HT1A and 5-HT1B receptor mutant mice. J Pharmacol Exp Ther 2001;298:1101-7
   PubMed Web of Science ®Google Scholar
• Duxon MS, Starr KR, Upton N. Latency to paroxetine-induced anxiolysis in the rat is reduced by co-administration of the 5-HT1A receptor antagonist WAY100635. Br J Pharmacol 2000;130:1713-19
   PubMed Web of Science ®Google Scholar
• Hogg S, Dalvi A. Acceleration of onset of action in schedule-induced polydipsia: combinations of SSRI and 5-HT1A and 5-HT1B receptor antagonists. Pharmacol Biochem Behav 2004;77:69-75
   PubMed Web of Science ®Google Scholar
• Owen RT. Vilazodone: a new treatment option for major depressive disorder. Drugs Today (Barc) 2011;47:531-7
   PubMed Web of Science ®Google Scholar
• Citrome L. Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract 2012;66:356-68
   PubMed Web of Science ®Google Scholar
• Singh M, Schwartz TL. Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use. Neuropsychiatr Dis Treat 2012;8:123-30
   PubMed Web of Science ®Google Scholar
• Choi E, Zmarlicka M, Ehret MJ. Vilazodone: a novel antidepressant. Am J Health Syst Pharm 2012;69:1551-7
   PubMed Web of Science ®Google Scholar
• Wang SM, Han C, Lee SJ, et al. A review of current evidence for vilazodone in major depressive disorder. Int J Psychiatry Clin Pract 2013; doi: 10.3109/13651501.2013.794245
   PubMed Web of Science ®Google Scholar
• Murck H, Frieboes RM, Antonijevic LA, Steiger A. Distinct temporal pattern of the effects of the combined serotonin-re-uptake inhibitor and 5-HT1A agonist EMD 68843. Psychopharmacology 2001;155:167-92
   Google Scholar
• Rabiner EA, Gunn RN, Wilkins MR, et al. Drug action at the 5-HT(1A) receptor in vivo: autoreceptor and postsynaptic receptor occupancy examined with PET and [carbonyl-(11)C]WAY-100635. Nucl Med Biol 2000;27:509-13
   PubMed Web of Science ®Google Scholar
• Rickels K, Athanasiou M, Robinson DS, et al. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2009;70:326-33
   PubMed Web of Science ®Google Scholar
• Khan A, Cutler AJ, Kajdasz DK, et al. A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder. J Clin Psychiatry 2011;72:441-7
   PubMed Web of Science ®Google Scholar
• Robinson DS, Kajdasz DK, Gallipoli S, et al. A 1-year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder. J Clin Psychopharmacol 2011;31:643-6
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Andersen HF, Lam RW. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J Psychiatry Neurosci 2006;31:122-31
   PubMed Web of Science ®Google Scholar
• Laughren TP, Gobburu J, Temple RJ, et al. Vilazodone: clinical basis for the US Food and Drug Administration's approval of a new antidepressant. J Clin Psychiatry 2011;72:1166-73
   PubMed Web of Science ®Google Scholar
• Lucki I. Behavioural studies of serotonin receptor agonists as antidepressant drugs. J Clin Psychiatry 1991;52:24-31
   PubMed Web of Science ®Google Scholar
• Jolas T, Schreiber R, Laporte AM, et al. Are postsynaptic 5-HT1A receptors involved in the anxiolytic effects of 5-HT1A receptor agonists and in their inhibitory effects on the firing of serotonergic neurons in the rat? J Pharmacol Exp Ther 1995;272:920-9
   PubMed Web of Science ®Google Scholar
• Feighner JP. Buspirone in the long-term treatment of generalized anxiety disorder. J Clin Psychiatry 1987;48:3-6
   PubMed Web of Science ®Google Scholar
• Cohn JB, Rickels K. A pooled, double-blind comparison of the effects of buspirone, diazepam and placebo in women with chronic anxiety. Curr Med Res Opin 1989;11:304-20
   PubMed Web of Science ®Google Scholar
• Cipriani A, Purgato M, Furukawa TA, et al. Citalopram versus other anti-depressive agents for depression. Cochrane Database Syst Rev 2012;7:CD006534
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Rizvi S. Sexual dysfunction, depression, and the impact of antidepressants. J Clin Psychopharmacol 2009;29:157-64
   PubMed Web of Science ®Google Scholar
• Kennedy S. Flibanserin: initial evidence of efficacy on sexual dysfunction, in patients with major depressive disorder. J Sex Med 2010;7:3449-59
   PubMed Web of Science ®Google Scholar
• Moll JL, Brown CS. The use of monoamine pharmacological agents in the treatment of sexual dysfunction: evidence in the literature. J Sex Med 2011;8:956-70
   PubMed Web of Science ®Google Scholar
• Katz M, Derogatis LR, Ackerman R, et al. Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the begonia trial. J Sex Med 2013;10:1807-15
   PubMed Web of Science ®Google Scholar
• Clayton AH, Kennedy SH, Edwards JB, et al. The effect of vilazodone on sexual function during the treatment of major depressive disorder. J Sex Med 2012; doi: 10.1111/jsm.12004
   Google Scholar